(Reuters) -Britain’s Oxford Biomedica on Monday maintained its annual forecasts for revenue and profit after it said first-half sales are expected to jump around 40% as orders remain strong for the cell and gene therapy developer and manufacturer.
(Reporting by Ankita Bora in Bengaluru)
